Devin Quinlan

🧬🚀 Biotech VC @ Breakout Fund.👨‍🔬Biological Engineering PhD @MIT. 🙆‍♂️ Fmr performer/director @improvboston. he/him. 🌶 Hot takes are my own

[Devin Quinlan @devinquinlan]

Grateful to be part of the "Survivor Tribal Council" of Academy Members for this year's NEVY awards in Life Sciences! Excited for the companies that were selected - hope you can join us to see the winners announced on December 5th! @NewEnglandVC https://t.co/HjLYLohAC0

[Devin Quinlan @devinquinlan]

@kulesatony Tony this was made for you haha

[Devin Quinlan @devinquinlan]

@Mykalt45 @BowTiedBiotech @Festivus159 @EricDai_BioE @davidkmyang I am skeptical that simply increasing neoantigens is enough to turn cold tumors hot. Curious where that has proven true in the clinic

[Devin Quinlan @devinquinlan]

@Mykalt45 @BowTiedBiotech @Festivus159 @EricDai_BioE @davidkmyang What is the proposed therapy? Direct injection into tumor, then some sort of immunotherapy? I'm not really sure why this would be better than a cancer vaccine.

[Devin Quinlan @devinquinlan]

@hannu @jeffvandermeer To me - reminded me of a combination of the last of us + iRobot. The idea of machines becoming sentient is very much science fiction.

[Devin Quinlan @devinquinlan]

So much of scientific research is focused on bringing science fiction to life. It’s amazing how many of our most important innovations first came from the minds of writers

[Christie Wilcox @NerdyChristie]

This robot is alive. Incorporated into its electronics are living fungal tissues that change the robot's behavior when exposed to intense light. That and more of the best from @ScienceMagazine and science in this edition of #ScienceAdviser: https://t.co/dpFdWgt11M

[Devin Quinlan @devinquinlan]

@varma_ashwin97 A few reasons:
- disconnect between early vs late stage investors in the life of a company (early investors often sell before commercialization)
- desire to mitigate technical risks by prioritizing programs with validated biology
- being wrong/ getting unlucky

[Devin Quinlan @devinquinlan]

Great examples of why first in class and best in class are so important in our industry - there are very few drugs that win on a given mechanism, in many cases just 1.

A ton of capital being spent developing insufficiently differentiated products that are perceived as “low risk”

[Professor Oak @Prof_Oak_]

What's driving that bimodal distribution? Differentiation, or lack thereof

Order of entry is incredibly important for undifferentiated drugs. Conversely, it plays a far lesser role for differentiated products. In both cases, avg. benchmarks under / overstate potl. share (3/4)

[Devin Quinlan @devinquinlan]

@omarabudayyeh If only he knew

[Devin Quinlan @devinquinlan]

@CNBCFastMoney @elevatebio great interview David!

[CNBC's Fast Money @CNBCFastMoney]

The disruptive potential for gene and cell therapies is taking center stage in the biotech business

@ElevateBio CEO & Chairman David Hallal talks his company's mission, the road ahead, and the potential impact these therapies could have on patients:

[Devin Quinlan @devinquinlan]

@EricTopol Imo you can’t draw that conclusion from those error bars.. especially when exercise + liraglutide is no different from liraglutide alone

[Devin Quinlan @devinquinlan]

Congrats to our new company Reunion Neuroscience on a $103M Series A! Reunion is a clinical-stage company developing novel psychedelic therapies for postpartum depression!

https://t.co/PCh37UHx2o

[Devin Quinlan @devinquinlan]

What a headline! Brought me back to AP Bio. Also - a very accurate takeaway from this year's AACR. @BioCentury

[Rami Rahal @ratatat79]

J&J’s William Hait highlighting the burden on pharma to launch products : 40 phase 1 ➡️ 3 BLAs! Hence $2B+ per drug launched. #AACR24 “Path to Entrepreneurship” session

[Devin Quinlan @devinquinlan]

Great writeup on DACs from @BioCentury! Lot of potential combinations of targets and payloads - looking forward to seeing the field evolve 🚀

https://t.co/gcrxZJU6uC

[BiotechTV @BiotechTV]

Company News: Nobel laureate @CarolynBertozzi on the launch of Firefly Bio and the science of degrader antibody conjugates.

Full video: https://t.co/IPPdIXgpFS

[Devin Quinlan @devinquinlan]

Excited to announce our newest portfolio company - Firefly Bio! Debuting with $94M, Firefly is pioneering degrader-antibody conjugates as an evolution to ADCs. MPM co-led the Series A financing with Versant Ventures, alongside Decheng and Lilly

https://t.co/VjPAeP5t5F

[Devin Quinlan @devinquinlan]

28% reduction in rate of heart attacks and 19% reduction in all-cause death for patients in this trial taking wegovy 🤯

[Adam Feuerstein ✡️ @adamfeuerstein]

BREAKING --> Wegovy cuts risk of heart attacks in milestone cardiovascular trial https://t.co/mmHbd6vWuG via @elaineywchen $NVO $LLY #AHA23

[MPM BioImpact @MPMBioImpact]

MPM BioImpact is pleased to participate in the Series A financing of AstronauTx to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. Read the press release: https://t.co/4VPUI7T5WJ